Blood Podcast: Season 1, Episode 35杭州棋牌室转让出租
In this week’s episode, we will review a study that identifies a new modular organization of erythropoiesis and offers a novel strategy to overcome chronic anemias, summarize a study that used data from two large phase three trials to examine the risk of thrombosis in patients with newly diagnosed multiple myeloma, and review the first report of autosomal recessive germline TET2 deficiency, which results in immunodeficiency, autoimmune lymphoproliferation, and lymphoma.
DeWolf and Tallman describe how they consider treatment options for patients with relapsed or refractory acute myeloid leukemia. While participation in clinical trials is highly desirable, they provide guidance on treatment with newer targeted agents when trials are not available or not suitable, taking both clinical and genetic factors into consideration.
Stremenova Spegarova and colleagues report the discovery of 3 children with autosomal germline deficiencies of the methylcytosine dioxygenase enzyme TET2, revealing that these deficiencies cause immunodeficiency, autoimmunity, and lymphoproliferation, including lymphomas. As well as highlighting the importance of TET2 for immune function, they also investigated its effect on hematopoiesis, finding modest perturbations in myelopoiesis.
Megakaryocyte TGFβ1 partitions erythropoiesis into immature progenitor/stem cells and maturing precursors杭州棋牌室转让出租
Di Giandomenico and colleagues demonstrate that megakaryocytes, through transforming growth factor β1 (TGFβ1) secretion or activation, play a key physiological role in regulating steady-state erythropoiesis, controlling 产品介绍ion of erythropoietin-responsive committed erythroid progenitors from 更多 immature cells. This takes us 1 step closer to understanding how the full cycle of red cell 产品介绍ion is regulated.
Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia杭州棋牌室转让出租
Gebru et al provide preclinical evidence that glucocorticoids can reduce survival of quizartinib-tolerant FLT3-mutant acute myeloid leukemia in cell lines and primary cells, both in vitro and in vivo. This provides a clinically testable strategy for maximizing reductions in leukemia burden and reducing the risk of relapse.
A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease杭州棋牌室转让出租
Petzer and colleagues tested the effect of an anti-BMP6 antibody that suppresses hepcidin in 2 rodent models of anemia of chronic disease. They demonstrate that inhibition of BMP improves systemic iron availability, improves erythropoietin responsiveness, and increases red cell production when combined with an erythropoiesis-stimulating agent.